Jpmorgan Chase & CO Tempest Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Tempest Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 77 shares of TPST stock, worth $524. This represents 0.0% of its overall portfolio holdings.
Number of Shares
77Holding current value
$524% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding TPST
# of Institutions
28Shares Held
2.04MCall Options Held
42.8KPut Options Held
72.9K-
Black Rock Inc. New York, NY550KShares$3.75 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA433KShares$2.95 Million0.0% of portfolio
-
Ubs Group Ag324KShares$2.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA298KShares$2.03 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA115KShares$780,1460.0% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $71M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...